Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -7643.91% is 472% below its 5-year average of -1335.88%, near the high end of its 5-year range (-439699800.00%–0.00%).
99.99% above its 12-month average of -87945017.61%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2023 (2023-12-31): -439699800.00%.
EBITDA MARGIN
-7643.91%
EBITDA MARGIN AVG TTM
-87945017.61%
EBITDA MARGIN AVG 3Y
-2298.91%
EBITDA MARGIN AVG 5Y
-1335.88%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.99%
CURRENT VS 3Y AVG
-232.50%
CURRENT VS 5Y AVG
-472.20%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Inhibikase Therapeutics, Inc.
Market Cap
$258.34M
EBITDA Margin
-7643.91%
TTM Avg
-87945017.61%
3Y Avg
-2298.91%
5Y Avg
-1335.88%
Market Cap
$259.30M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.48M
EBITDA Margin
-768.62%
TTM Avg
-551.06%
3Y Avg
-374.75%
5Y Avg
-290.29%
Market Cap
$258.00M
EBITDA Margin
-1857.26%
TTM Avg
-1020.57%
3Y Avg
-1032.24%
5Y Avg
-903.20%
Market Cap
$257.09M
EBITDA Margin
-4.72%
TTM Avg
-1.10%
3Y Avg
6.56%
5Y Avg
4.38%
Market Cap
$255.08M
EBITDA Margin
-1.78%
TTM Avg
-948.17%
3Y Avg
-2570.36%
5Y Avg
-2570.36%
Market Cap
$250.48M
EBITDA Margin
-9077.06%
TTM Avg
-6066.11%
3Y Avg
-4339.03%
5Y Avg
-4339.03%
Market Cap
$272.17M
EBITDA Margin
-2082.59%
TTM Avg
-1743.06%
3Y Avg
-1015.79%
5Y Avg
-806.48%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $258.34M | -7643.91% | -87945017.61% | -2298.91% | -1335.88% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $258.48M | -768.62% | -551.06% | -374.75% | -290.29% |
| AC Immune S.A. (ACIU)vs › | $258.00M | -1857.26% | -1020.57% | -1032.24% | -903.20% |
| Anika Therapeutics, Inc. (ANIK)vs › | $257.09M | -4.72% | -1.10% | 6.56% | 4.38% |
| Century Therapeutics, Inc. (IPSC)vs › | $255.08M | -1.78% | -948.17% | -2570.36% | -2570.36% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $250.48M | -9077.06% | -6066.11% | -4339.03% | -4339.03% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | -2082.59% | -1743.06% | -1015.79% | -806.48% |
| Invivyd, Inc. (IVVD)vs › | $241.61M | -100.05% | -392.29% | -392.29% | -392.29% |
Gross Margin
0.0%
EBITDA Margin
-7643.9%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2023-12-31 | -439699800.00% |
| 2023-09-30 | -5985.13% |
| 2023-06-30 | -5191.30% |
| 2023-03-31 | -7299.92% |
| 2022-12-31 | -6811.71% |
| 2022-09-30 | -61876.53% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | -93.61% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 6.76% |
| 2017-03-31 | 0.00% |
